Adalimumab Biosimilar – Anti-TNF alpha mAb – Research Grade

Reference:
1 review Write a review
Size

,

Brand

Product type

Clonality

Expression system

Applications

,

Product nameAdalimumab Biosimilar - Anti-TNF alpha mAb - Research Grade
SourceDrugBank DB00051
SpeciesHuman
Expression systemMammalian
Molecular weight144kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
ApplicationsELISA,WB
Aliases /SynonymsAdalimumab,Adalimumab,TNF alpha,anti-TNF alpha
ReferencePX-TA1001
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Adalimumab Biosimilar - Anti-TNF alpha mAb - Research Grade

General information about Adalimumab

Adalimumab is a recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.

Adalimumab Biosimilar - Anti-TNF alpha mAb binds to Human TNFa/TNF-alpha in indirect ELISA Assay

Immobilized Human TNFa Recombinant Protein (cat. No. PX-P3058) at 0.5µg/mL (100µL/well) can bind Adalimumab Biosimilar - Anti-TNF alpha mAb (cat. No. PX-TA1001) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 142.1M.

SDS-PAGE for Adalimumab Biosimilar - Anti-TNF alpha mAb

Adalimumab Biosimilar - Anti-TNF alpha mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Reviews

  • Ofer Gover

    We used this ab to reduce as a negative control for reducing caco-2 (IEC) cells exitation by exugenues TNFa. We measured IL8 secreation as a result of TNFa stimulation. 1ug/mL ofAdalimumab Biosimilar – Anti-TNF alpha mAb was enough to completly abolish IL8 secreation by TNFa stimulation in caco-2 cells.

REVIEW YOUR PRODUCT

Add a review

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products